PRAX | Praxis Precision Medicines, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	58.15 - 61.70
52 Week Range	13.01 - 67.21
Beta	2.98
Implied Volatility	91.76%
IV Rank	17.72%
Day's Volume	274,368
Average Volume	352,490
Shares Outstanding	17,757,100
Market Cap	1,035,061,359
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-16

Valuation
Profitability
Growth
Health
P/E Ratio	-10.43
Forward P/E Ratio	N/A
EPS	-5.59
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	82
Country	USA
Website	PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX's peers: GTBP, MOLN, MLYS, ANTX, PHVS, PEPG, THRX, PMVP, CGEM, ELVN, IMRX, ANEB, ELYM, HCWB, STOK, EWTX, CRNX, DYN, RVMD, VRPX, TOVX

*Chart delayed

Analyzing fundamentals for PRAX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see PRAX Fundamentals page.

Watching at PRAX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PRAX Technicals page.